A win for antisense: Isis/Genzyme score US OK for Kynamro
This article was originally published in Scrip
A month after a competitor's drug was approved, Genzyme and Isis Pharmaceuticals gained the US FDA's nod to market Kynamro (mipomersen sodium) to treat patients with homozygous familial hypercholesterolemia (HoFH), a rare genetic lipid disorder that causes extremely high elevations of low-density lipoprotein cholesterol (LDL-C), causing early onset of arthrosclerosis, with patients often experiencing heart attacks in their early teens, often dying before age 30.
You may also be interested in...
Three and a half months after Ionis Pharmaceuticals Inc. surprised investors with the news that Sanofi's Genzyme business unit would no longer market Kynamro (mipomersen) for homozygous familial hypercholesterolemia (HoFH), the Carlsbad, California-based biotechnology company revealed that it sold global rights to the cholesterol-lowering drug to Kastle Therapeutics LLC for up to $95m.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.